Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $49.75, for a total transaction of $936,892.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Clay B. Siegall also recently made the following trade(s):
- On Thursday, January 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $51.71, for a total transaction of $973,802.72.
- On Monday, December 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $55.40, for a total transaction of $1,043,292.80.
Seattle Genetics, Inc. (NASDAQ SGEN) traded down $0.16 during trading hours on Tuesday, hitting $52.15. 988,590 shares of the company were exchanged, compared to its average volume of 1,420,000. The stock has a market cap of $7,510.00, a PE ratio of -58.60 and a beta of 2.08. Seattle Genetics, Inc. has a 1 year low of $45.31 and a 1 year high of $71.32.
Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. The firm had revenue of $129.61 million during the quarter, compared to analysts’ expectations of $123.99 million. Seattle Genetics had a negative net margin of 26.03% and a negative return on equity of 33.36%. The firm’s quarterly revenue was up 23.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.39) EPS. analysts forecast that Seattle Genetics, Inc. will post -1.58 EPS for the current year.
SGEN has been the subject of several analyst reports. Zacks Investment Research cut shares of Seattle Genetics from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Barclays increased their price target on shares of Seattle Genetics from $55.00 to $60.00 and gave the company an “equal weight” rating in a research note on Monday, October 16th. Guggenheim reissued a “buy” rating and issued a $72.00 price target on shares of Seattle Genetics in a research note on Monday, October 23rd. Jefferies Group reissued a “buy” rating and issued a $53.00 price target on shares of Seattle Genetics in a research note on Thursday, October 26th. Finally, Bank of America raised shares of Seattle Genetics from an “underperform” rating to a “neutral” rating in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Seattle Genetics presently has an average rating of “Hold” and a consensus price target of $64.56.
Several large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in shares of Seattle Genetics by 2.9% during the 4th quarter. BlackRock Inc. now owns 7,756,494 shares of the biotechnology company’s stock worth $414,975,000 after purchasing an additional 220,955 shares during the period. Capital International Investors lifted its holdings in Seattle Genetics by 63.7% during the 3rd quarter. Capital International Investors now owns 4,460,246 shares of the biotechnology company’s stock worth $242,682,000 after buying an additional 1,735,657 shares in the last quarter. Manning & Napier Advisors LLC acquired a new stake in Seattle Genetics during the 3rd quarter worth approximately $140,098,000. Pictet Asset Management Ltd. lifted its holdings in Seattle Genetics by 79.3% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,266,426 shares of the biotechnology company’s stock worth $68,906,000 after buying an additional 560,110 shares in the last quarter. Finally, Capital Guardian Trust Co. lifted its holdings in Seattle Genetics by 82.2% during the 3rd quarter. Capital Guardian Trust Co. now owns 1,064,300 shares of the biotechnology company’s stock worth $57,909,000 after buying an additional 480,044 shares in the last quarter. 91.60% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Clay B. Siegall Sells 18,832 Shares of Seattle Genetics, Inc. (SGEN) Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/clay-b-siegall-sells-18832-shares-of-seattle-genetics-inc-sgen-stock.html.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.